<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32833724</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-1611</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of clinical neuromuscular disease</Title><ISOAbbreviation>J Clin Neuromuscul Dis</ISOAbbreviation></Journal><ArticleTitle>Positive Cytosolic 5-Nucleotidase 1A Antibodies in Motor Neuron Disease.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>52</EndPage><MedlinePgn>50-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CND.0000000000000278</ELocationID><Abstract><AbstractText>Inclusion body myositis (IBM) is the most common acquired myopathy in adults older than 50 years. Muscle biopsy remains the gold standard for diagnosis. Recently described serum antibodies against cytosolic 5-nucleotidase 1A (cN1A) are considered highly specific for IBM. However, positive cN1A antibodies in diseases other than IBM are recently reported. We review 2 cases in which serum antibodies were positive but ancillary testing revealed motor neuron disease. A 68-year-old man presented with asymmetric quadriceps and handgrip weakness prompting concern for IBM. However, electromyography showed purely chronic neurogenic abnormalities, and muscle biopsy was consistent with post-polio syndrome. A 60-year-old woman reported a history of progressive muscle weakness. Despite positive antibodies, examination and electromyography were indicative of amyotrophic lateral sclerosis. Serum cN1A antibodies are not 100% specific for the diagnosis of IBM. Careful clinical, electrophysiologic, and histopathologic correlation is required in workup of individuals with neuromuscular weakness and positive antibodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assadi</LastName><ForeName>Rami-James K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota-Twin Cities, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manousakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Neuromuscul Dis</MedlineTA><NlmUniqueID>100887391</NlmUniqueID><ISSNLinking>1522-0443</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.5</RegistryNumber><NameOfSubstance UI="D015720">5'-Nucleotidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.5</RegistryNumber><NameOfSubstance UI="C552626">NT5C1A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015720" MajorTopicYN="N">5'-Nucleotidase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018979" MajorTopicYN="N">Myositis, Inclusion Body</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32833724</ArticleId><ArticleId IdType="doi">10.1097/CND.0000000000000278</ArticleId><ArticleId IdType="pii">00131402-202009000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83:426&#x2013;433.</Citation></Reference><Reference><Citation>Benjamin Larman H, Salajegheh M, Nazareno R, et al. Cytosolic 5&#x2032;-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73:408&#x2013;418.</Citation></Reference><Reference><Citation>Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5&#x2032;-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016;75:696&#x2013;701.</Citation></Reference><Reference><Citation>Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 5&#x2032;-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73:397&#x2013;407.</Citation></Reference><Reference><Citation>Liewluck T. Anti-cytosolic 5&#x2019;-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases. Neurology. 2017;89:2017&#x2013;2018.</Citation></Reference><Reference><Citation>Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry. 2016;87:373&#x2013;378.</Citation></Reference><Reference><Citation>Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5&#x2032;-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken). 2016;68:66&#x2013;71.</Citation></Reference><Reference><Citation>Volont&#xe9; C, Apolloni S, Parisi C, et al. Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology. 2016;104:180&#x2013;193.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>